Use Of An In Vitro Whole Blood Depletion ASSAY To Compare The Efficacy Of B CELL Depleting Agents In Patients With Systemic LUPUS Erythematosus

Venkat Reddy¹, Geraldine Cambridge², D.A. Isenberg³, Mark Cragg⁴ and Maria Leandro⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom, ⁵Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Antibodies, B cell targeting, B cells, systemic lupus erythematosus (SLE) and therapeutic targeting

Session Information

Session Title: B cell Function and Targeting in Systemic Lupus Erythematosus

Session Type: Abstract Submissions (ACR)

Background/Purpose: Variability in clinical response to B-cell depletion therapy (BCDT) with the anti-CD20mAb rituximab (RTX) has been well described in Systemic Lupus Erythematosus (SLE). Poor clinical response is associated with incomplete depletion which suggests that improving the efficiency of depletion might result in improved therapeutic outcome. GA101 is a recombinant, afucosylated fully human type II anti-CD20 mAb that has shown more effective depletion and clinical response in phase II trials in lymphoma. We have therefore compared the in vitro B-cell cytotoxicity (cytotoxicity index, CTI) of BHH2 (glycosylated GA101) with RTX, in lymphocytes from patients with SLE.

Methods: We included 23 patients with SLE, who met the American College of Rheumatology revised classification criteria. An in vitro autologous whole blood depletion assay (WBD) was used to assess the CTI. Briefly, 100μl of heparinised blood was incubated with either RTX, BHH2 or without antibody, at a concentration of 1μg/ml at 37ºC, 5% CO₂for 24hours. Samples were then analysed by flow cytometry for CD45 (all lymphocytes), CD3 (T cells) and CD19 (B cells). The CTI was calculated using the formula:CTI of mAb=100-[(number of B:Tcells in sample without antibody-number of B:Tcells with mAb)/number of B:T cells in sample without antibody) X 100] and the mean from triplicate well calculated. The relationship between the relative expression (mean fluorescence intensity;MFI) of CD20 and CD32B (FcgRIIB) on B cells and CTI was determined using spearman rank correlation. Concurrent clinical and laboratory parameters including anti-dsDNA and C3 were collected and assessed.

Results: The mean CTI of BHH2 was higher than RTX in all but one patient. Median CTI in 23 SLE patients was 20% (range9-70) and 15% (range 1-42), for BHH2 and RTX, respectively (p=0.0002). CTI was <25% in 5 (21%) and 16 (73%) patients, for BHH2 and RTX, respectively. The mean±SD MFI of CD20 and CD32B on SLE-B cells was 9079±4025 and 4223±1587, respectively. The CTI of neither mAb correlated with the expression of CD20 (r²=-0.332,0.204, for BHH2 and RTX, respectively). Also, there was no correlation between the CTI of mAbs and lymphocyte-count, serum creatinine, total IgG, C3, positivity for ENAs or anti-dsDNA.

Conclusion: These results indicate that BHH2 is superior to RTX at inducing cytotoxicity in vitro in B cells from patients with SLE. This study provides the preliminary data to consider type II mAbs (GA101-like) as an alternative BCD agent for SLE in a clinical trial setting.

Disclosure:

V. Reddy,
None;

G. Cambridge,
None;

D. A. Isenberg,
None;

M. Cragg,
None;

M. Leandro,
None.

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-an-in-vitro-whole-blood-depletion-assay-to-compare-the-efficacy-of-b-cell-depleting-agents-in-patients-with-systemic-lupus-erythematosus/